Search Results - "Hesselink, D.A."

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations by Tang, J T, Andrews, L M, van Gelder, T, Shi, Y Y, van Schaik, R H N, Wang, L L, Hesselink, D A

“…Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and…”
Get more information

Acute Kidney Injury Is Highly Frequent Early After LVAD Implantation, with High Morbidity and Mortality Rates: A Multi-Centre Study by Muslem, R, Caliskan, K, Akin, S, Hesselink, D.A, Whitman, G.J, Tedford, R.J, Bogers, A.J, Manintveld, O.C, Russell, S.D

Get full text

Proteinuria in Patients Receiving Left Ventricular Assist Devices Is Highly Associated with Renal Failure and Mortality by Muslem, R, Caliskan, K, Akin, S, Hesselink, D.A, Whitman, G, Tedford, R.J, Bogers, A.J, Manintveld, O.C, Russell, S.D

Get full text

Monocyte profiles in kidney transplant recipients: Stable grafts vs. rejection by Vereyken, E.J.F, Kraaij, M.D, Hilbrands, L.B, Leenen, P.J.M, Hesselink, D.A, van den Bosch, T.P.P, Baan, C.C, Betjes, M.G.H, Rowshani, A.T

Get full text

Neutrophil gelatinase-associated lipocalin, but not kidney injury marker-1, correlates with duration of delayed graft function by van den Akker, E.K, Hesselink, D.A, Manintveld, O.C, IJzermans, J.N.M, de Bruin, R.W.F, Dor, F.J.M.F

Get full text

High intra-patient variability in tacrolimus clearance does not predict progression of cardiac allograft vasculopathy after heart transplantation by Bouamar, R, Shuker, N, Hesselink, D.A, Van Gelder, T, Caliskan, K, Manintveld, O.C, Balk, A.H.M.M, Constantinescu, A.A

Get full text

Kinetic analysis reveals potency of CD4+ CD25bright+ regulatory T-cells in kidney transplant patients by Velthuis, J.H.L, Hesselink, D.A, Hendrikx, T.K, van der Mast, B.J, Klepper, M, de Greef, G.E, Baan, C.C, Weimar, W

“…Abstract Donor-specific hyporesponsiveness as occurs after allogeneic kidney transplantation may be mediated by repression of effector cells by a specific…”
Get full text

Best Practices to Implement Dried Blood Spot Sampling for Therapeutic Drug Monitoring in Clinical Practice by Francke, Marith I., Peeters, Laura E.J., Hesselink, D.A., Kloosterboer, Sanne M., Koch, Birgit C.P., Veenhof, Herman, de Winter, Brenda C.M.

Get full text

RESISTANT HYPERTENSION IMPROVED AFTER 3 AND 6 MONTHS BY MEASURING DRUG LEVELS TO IDENTIFY NON-ADHERENCE by Peeters, Laura, Kappers, M.H.W., Hesselink, D.A., Net, J.B. Van Der, Hartong, S.C.C., Bahmany, S., Massay, E., Dijk, L. Van, Gelder, T. Van, Koch, B.C.P., Versmissen, J.

“…Objective: Identification of non-adherence to antihypertensive drugs is crucial to improve resistant hypertension (RH). For this measuring drug levels is the…”
Get full text

Global Transplantation COVID Report March 2020 by Ahn, C., Amer, H., Anglicheau, D., Ascher, N.L., Baan, C.C., Battsetset, G., Bat-Ireedui, B., Berney, T., Betjes, M.G.H., Bichu, S., Birn, H., Brennan, D., Bromberg, J., Caillard, S., Cannon, R.M., Cantarovich, M., Chan, A., Chen, Z.S., Chapman, J.R., Cole, E.H., Cross, N., Durand, F., Egawa, H., Emond, J.C., Farrero, M., Friend, P.J., Geissler, E.K., Ha, J., Haberal, M.A., Henderson, M.L., Hesselink, D.A., Humar, A., Jassem, W., Jeong, J.C., Kaplan, B., Kee, T., Kim, S.J., Kumar, D., Legendre, C.M., Man, K., Moulin, B., Muller, E., Munkhbat, R., Od-Erdene, L., Perrin, P., Rela, M., Tanabe, K., Tedesco Silva, H., Tinckam, K.T., Tullius, S.G., Wong, G.

Get full text

High Tacrolimus Intra-Patient Variability and Subtherapeutic Immunosuppression Are Associated with Adverse Kidney Transplant Outcomes by Mendoza Rojas, A., Hesselink, D.A., van Besouw, N.M., Dieterich, M., de Kuiper, P., Baan, C.C., van Gelder, T

Get full text

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation by Shuker, N., Bouamar, R., Schaik, R. H. N., Clahsen‐van Groningen, M. C., Damman, J., Baan, C. C., Wetering, J., Rowshani, A. T., Weimar, W., Gelder, T., Hesselink, D. A.

“…Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This…”
Get full text

Donor-Derived Cell-Free DNA for the Detection of Heart Allograft Injury: Impact of Timing of the Liquid Biopsy by Verhoeven, J.G., Hesselink, D.A., Peeters, A.M., de Jonge, E., von der Thüsen, J.H., van Schaik, R.H., Baan, C.C., Manintveld, O., Boer, K.

“…In heart transplant recipients, donor-derived cell-free DNA (ddcfDNA) is a potential biomarker for acute rejection (AR), in that increased values may indicate…”
Get full text

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized‐Controlled Clinical Trials by Bouamar, R., Shuker, N., Hesselink, D. A., Weimar, W., Ekberg, H., Kaplan, B., Bernasconi, C., Gelder, T.

“…Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration–effect relationship for Tac is poorly defined. This…”
Get full text

(1094) - Effect of Different Treatment Modalities for End-stage Renal Disease After Heart Transplantation by Roest, S., Hesselink, D.A., Kardys, I., Caliskan, K., Brugts, J.J., Maat, A.P., Constantinescu, A.A., Manintveld, O.C.

Get full text

Personalized immunosuppression in elderly renal transplant recipients by Peeters, L.E.J., Andrews, L.M., Hesselink, D.A., de Winter, B.C.M., van Gelder, T.

“…[Display omitted] The number of elderly people has increased considerably over the last decades, due to a rising life expectancy and ageing populations. As a…”
Get full text

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial by Peeters, Laura E J, Kappers, M H W, Hesselink, D A, van der Net, J B, Hartong, S C C, van de Laar, R, Ezzahti, M, van de Ven, P J G, van der Meer, I M, de Bruijne, E L E, Kroon, A A, Indhirajanti-Tomasoa, S, van der Linde, N A J, Bahmany, S, Boersma, E, Massey, E K, van Dijk, L, van Gelder, T, Koch, Birgit C P, Versmissen, Jorie

“…Adherence to antihypertensive drugs (AHDs) is crucial for controlling blood pressure (BP). We aimed to determine the effectiveness of measuring AHD…”
Get full text

The prevalence of osteopenia and osteoporosis after heart transplantation assessed using CT by Roest, S., Budde, R.P.J., Hesselink, D.A., Zijlstra, F., Zillikens, M.C., Caliskan, K., Bos, D., Manintveld, O.C.

“…Osteoporosis is frequently observed in patients after heart transplantation (HT), although the prevalence long-term post-HT is unknown. Most studies…”
Get full text

5804Predictive value of right heart hemodynamics on the development of acute kidney injury early after heart transplantation by Guven, G., Manintveld, O., Brankovic, M., Brugts, J., Constantinescu, A.A., Akin, S., Hesselink, D.A., Birim, O., Caliskan, K.

Get full text

Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients by Meijers, R. W. J., Litjens, N. H. R., Hesselink, D. A., Langerak, A. W., Baan, C. C., Betjes, M. G. H.

“…Cytomegalovirus (CMV) infection profoundly affects the T cell compartment and is associated with alterations in T cell aging parameters and generation of…”
Get full text